Biological Assembly 1  

 3D View: Structure | 1D-3D View | Electron Density | Validation Report | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Biological Assembly 2  

 3D View: Structure | 1D-3D View | Electron Density | Validation Report | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 2 assigned by authors.

Macromolecule Content

• Total Structure Weight: 69.99 kDa 
• Atom Count: 4360 
• Modelled Residue Count: 531 
• Deposited Residue Count: 606 
• Unique protein chains: 1

6RLN

Crystal structure of RIP1 kinase in complex with GSK3145095

• PDB DOI: 10.2210/pdb6RLN/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Baculovirus expression vector pFastBac1-HM
• Mutation(s): Yes 


• Deposited: 2019-05-02 Released: 2019-07-03 
• Deposition Author(s): Thorpe, J.H., Harris, P.A.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.87 Å
• R-Value Free: 0.232 
• R-Value Work: 0.194 
• R-Value Observed: 0.196 

Literature

Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.

Harris, P.A., Marinis, J.M., Lich, J.D., Berger, S.B., Chirala, A., Cox, J.A., Eidam, P.M., Finger, J.N., Gough, P.J., Jeong, J.U., Kang, J., Kasparcova, V., Leister, L.K., Mahajan, M.K., Miller, G., Nagilla, R., Ouellette, M.T., Reilly, M.A., Rendina, A.R., Rivera, E.J., Sun, H.H., Thorpe, J.H., Totoritis, R.D., Wang, W., Wu, D., Zhang, D., Bertin, J., Marquis, R.W.

(2019) ACS Med Chem Lett 10: 857-862

• PubMed: 31223438 
• DOI: 10.1021/acsmedchemlett.9b00108
• Primary Citation of Related Structures:  
  6RLN


• PubMed Abstract: 
  

RIP1 regulates cell death and inflammation and is believed to play an important role in contributing to a variety of human pathologies, including immune-mediated inflammatory diseases and cancer. While small-molecule inhibitors of RIP1 kinase have been advanced to the clinic for inflammatory diseases and CNS indications, RIP1 inhibitors for oncology indications have yet to be described. Herein we report on the discovery and profile of GSK3145095 (compound 6 ). Compound 6 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking RIP1 kinase-dependent cellular responses. Highlighting its potential as a novel cancer therapy, the inhibitor was also able to promote a tumor suppressive T cell phenotype in pancreatic adenocarcinoma organ cultures. Compound 6 is currently in phase 1 clinical studies for pancreatic adenocarcinoma and other selected solid tumors.

---

Organizational Affiliation: 

Pattern Recognition Receptor DPU and Medicinal Science & Technology, GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Receptor-interacting serine/threonine-protein kinase 1	A, B	303	Homo sapiens	Mutation(s): 4  Gene Names: RIPK1, RIP, RIP1 EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for Q13546 (Homo sapiens) Explore Q13546  Go to UniProtKB:  Q13546
PHAROS:  Q13546 GTEx:  ENSG00000137275

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
K8K (Subject of Investigation/LOI)	C [auth A], D [auth B]	~{N}-[(3~{S})-7,9-bis(fluoranyl)-2-oxidanylidene-1,3,4,5-tetrahydro-1-benzazepin-3-yl]-3-(phenylmethyl)-1~{H}-1,2,4-triazole-5-carboxamide C20 H17 F2 N5 O2 ATQAGKAMBISZQM-HNNXBMFYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.87 Å
• R-Value Free: 0.232 
• R-Value Work: 0.194 
• R-Value Observed: 0.196 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 101.84	α = 90
b = 130.79	β = 90
c = 48.83	γ = 90

Software Package:

Software Name	Purpose
BUSTER	refinement
XDS	data reduction
Aimless	data scaling
PHASER	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2019-05-02 
• Released Date: 2019-07-03 
Deposition Author(s): Thorpe, J.H., Harris, P.A.

Revision History  

• Version 1.0: 2019-07-03
  Type: Initial release